INTRODUCTION
Hoofnagle and colleagues 1 first used interferon alpha as a potential treatment for patients with non-A non-B chronic hepatitis. Thereafter the combination of interferon and ribavirin were the main treatment agents for chronic hepatitis C. Many new direct-acting antiviral agents are now a part of treatment for chronic hepatitis C, but pegylated interferon (PEG-IFN) is still being used, especially for genotype 2, in Korea. However, PEG-IFN has a number of adverse effects, some severe enough to require halting interferon treatment.
Dermatological adverse events induced by PEG-IFN include pruritus, alopecia, dermatitis, dry skin, and injection site infection. 2 There are some case reports of panniculitis induced by PEG-IFN-, [3] [4] [5] but only one case report about panniculitis induced by PEG-IFN- was published in Korea. 6 There is no report of repeated occurrences of panniculitis induced by PEG-IFN-. So we report a case of repeated panniculitis induced by PEG-IFN- 2a, with literature review.
CASE REPORT
A 50-year-old woman with body weight of 44 kg was admitted because of tenderness in the left lower abdomen accompanied by a nodule that occurred one day prior. Skin color at the site was reddish, and the nodule size was about 6×6 cm ( Fig. 1 ). Although interferon  has a dual (direct antiviral and immunomodulatory) effect on hepatitis C, a wide spectrum of adverse effects has been noted. 11 Several side effects such Panniculitis can be defined as an inflammation of the subcutaneous tissues. 12 Pathologically there are two broad types, septal and lobular, although most lesions are composed of a mixture of each ( Fig. 4) . Ter Poorten and Thiers 13 classified panniculitis by its primary histopathologic pattern:
( 13 Panniculitis induced by interferon appears most common in patients with multiple sclerosis. [3] [4] [5] The pathogenesis of the panniculitis induced by interferon has not been described completely. Heinzerling et al. 4 Inafuku et al. 15 reported that skin reactions associated with interferon beta-1b subcutaneous injection were dependent on the depth of injection and that no local reactions occurred following deep subcutaneous injection. They suggested that local cytokine-mediated mechanisms may initiate adverse immune reactions or that non-specific inflammation may be more likely to follow intradermal administration, and recommended vertical injection with the aim of injecting interferon into deep subcutaneous fatty tissues.
Therefore patients need to be educated to properly inject into the skin in order to avoid panniculitis.
In conclusion, we report a case of panniculitis as a very rare side effect of PEG-IFN- 2a. Physicians should be aware and manage this rare complication properly. Considering that it might be caused by inappropriate self-injection technique, patients should be educated in injection technique to prevent or decrease local skin reactions including panniculitis.
